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Abstract
Protein-carbohydrate interactions are important for glycoprotein structure and function. Antibodies of the IgG class, with
increasing significance as therapeutics, are glycosylated at a conserved site in the constant Fc region. We hypothesized that
disruption of protein-carbohydrate interactions in the glycosylated domain of antibodies leads to the exposure of
aggregation-prone motifs. Aggregation is one of the main problems in protein-based therapeutics because of
immunogenicity concerns and decreased efficacy. To explore the significance of intramolecular interactions between
aromatic amino acids and carbohydrates in the IgG glycosylated domain, we utilized computer simulations, fluorescence
analysis, and site-directed mutagenesis. We find that the surface exposure of one aromatic amino acid increases due to
dynamic fluctuations. Moreover, protein-carbohydrate interactions decrease upon stress, while protein-protein and
carbohydrate-carbohydrate interactions increase. Substitution of the carbohydrate-interacting aromatic amino acids with
non-aromatic residues leads to a significantly lower stability than wild type, and to compromised binding to Fc receptors.
Our results support a mechanism for antibody aggregation via decreased protein-carbohydrate interactions, leading to the
exposure of aggregation-prone regions, and to aggregation.
Citation: Voynov V, Chennamsetty N, Kayser V, Helk B, Forrer K, et al. (2009) Dynamic Fluctuations of Protein-Carbohydrate Interactions Promote Protein
Aggregation. PLoS ONE 4(12): e8425. doi:10.1371/journal.pone.0008425
Editor: Laurent Kreplak, Dalhousie University, Canada
Received September 7, 2009; Accepted November 30, 2009; Published December 23, 2009
Copyright:  2009 Voynov et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Novartis Pharma AG. Employees of Novartis participated in study design, data collection and analysis, and preparation of
the manuscript.
Competing Interests: The authors declare competing financial interests. The authors Bernhard Helk, Kurt Forrer, Heidi Zhang, Cornelius Fritsch, and Holger
Heine are current employees of Novartis Pharma AG. This work was supported by Novartis Pharma AG.
* E-mail: trout@mit.edu
Introduction
Protein glycosylation is a ubiquitous post-translational modifi-
cation in cells. Many cell-surface and extracellular proteins are
glycosylated, and play key structural and functional biological roles
especially with respect to immunity and cell-cell recognition
[1,2,3]. Protein glycosylation is also of substantial importance in
Pharmacology. At least one third of approved protein therapeutics
are glycoproteins [4]. Protein-carbohydrate interactions are
involved in many molecular and cellular events such as cancer
and lectin biology, cell adhesion and aggregation, and protein
stability and function. For example, alternative protein glycosyl-
ation patterns are utilized or assessed as biomarkers of several
cancer types [5,6], where erroneous glycosylation perturbs native
protein-carbohydrate interactions and cell adhesion. Differences in
protein glycosyaltion of blood group antigens [7,8,9] also account
for antibody-mediated agglutination of red blood cells when
human ABO blood types are mismatched. Glycosylation of
pharmaceutical erythropoietin has been engineered for improved
in vivo stability and erythropoetic activity [10]. Glycosylation in the
Fc region of IgG antibodies influences effector function via binding
to Fc receptors, and antibody glycoforms with desired effector
properties can be engineered [11,12,13]. Thus, protein glycosyl-
ation represents a structural variation of biological and pharma-
ceutical importance, especially with respect to protein stability, cell
adhesion and aggregation.
While the discovery of protein-based and especially antibody
therapeutics has seen a significant growth [14,15], protein stability
remains one of the most challenging tasks. Proteins undergo
constant structural fluctuations leading to instability and loss of
native monomer over time [16,17]. Protein aggregation is the most
common form of native monomer loss, and is deleterious not only
because it may cause reduced therapeutic efficacy, but also
because it may elicit an immune reaction in patients [18]. Protein
aggregation is generally thought to occur via partially unfolded
intermediates that with time and upon stress can form energet-
ically-favorable aggregates. Understanding the aggregation mech-
anisms of therapeutic antibodies and other proteins would permit
rational design of stabilization strategies.
Monoclonal antibodies (MAbs) are Y-shaped molecules com-
prising two Fab and one Fc domains, and are composed of two
light and two heavy chains. The two heavy chains are further
distinguished as chain A and chain B, and contain one variable
domain, VH, and three constant domains for IgG, CH1, CH2, and
CH3 (Figure 1A). Variable complementarity determining regions
(CDRs) in the light and heavy chains of antibodies confer their
tremendous diversity and hence the therapeutic opportunity to use
biomarker-specific antibodies as pharmaceuticals. Of the different
classes of antibodies, IgG, and more specifically isotype IgG1 and
to a smaller extent IgG4 and IgG2, are most commonly used as
biopharmaceuticals [19]. IgG MAbs are multidomain proteins
with distinct melting transitions for Fab, CH2 and CH3 [20,21]. In
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variable regions, CH2 is the domain with the lowest melting
temperature. The human IgG CH2 domain is glycosylated at a
single site, Asn297 (Figure 1A and 1B).
Carbohydrates can form a variety of non-covalent bonds with
protein residues [22], and a ranking of sugar interface propensity
for all amino acids has been proposed [23]. The hydroxyl groups
of sugars make hydrogen bonds with amino acids such as Asp,
Glu, Lys, Arg, His. At the same time, a hexose can have a
conformation such that several of its carbon atoms are in a cluster
that forms energetically favorable CH-pi interactions with parallel
aligned aromatic rings, of for example Phe, Tyr or Trp [22,24].
Two essential requirements listed for CH-pi interactions are that
the sugar and aromatic rings are face to face and that they are less
than 4A ˚ apart. The N-glycosylation of an IgG antibody at a
conserved residue, Asn297, exemplifies both of these types of
interactions. Structural analysis of the antibody Fc region indicates
a number of interactions between CH2 inner surface amino acids
and neighboring carbohydrates [25,26]. In particular, CH-pi
interactions can form between sugars and the aromatic amino
acids Tyr296, Phe241, Phe243 on each of the two chains in CH2.
Crystal structures of human IgG-Fc show that Phe243 forms
contact with GlcNAc [26].
There is a plethora of reports that compare different IgG
glycovariants in stability and function. For example, gradual
truncation of the carbohydrates at Asn297 in isolated Fc domains
leads to a gradual decrease of the CH2 melting temperature (Tm),
with the least stable being the fully deglycosylated Fc [12]. A
decrease in the melting temperature of the CH2 domain upon
deglycosylation is observed for full antibodies as well [21].
Aglycosylated IgG also shows higher exposure of hydrophobic
sites compared to native IgG [27]. IgG glycovariants that lack
galactose (G0) have higher degree of mobility than their
galactosylated (G1 and G2) counterparts, as evidenced by NMR
analysis [28]. Moreover, increased surface exposure of GlcNAc in
G0 glycovariants is associated with higher binding to mannose-
binding protein (MBP) [29]. Another comparison indicates that
the presence of terminal sialic acid in the Fc carbohydrates leads to
increased anti-inflammatory properties of IgG [3].
At the same time, the aggregation mechanisms of natively
glycosylated antibody domains remain unknown. The work
presented here originated from the observation that the most
hydrophobic motifs within Fc lie at the protein-carbohydrate
interface in CH2, and that there are two aromatic amino acids in
that region, Phe241 and Phe243. Thus, we hypothesized that
disruption of sugar-protein, and more specifically CH-pi, interac-
tions leads to exposure of aggregation-prone regions and to protein
aggregation. We utilized a human IgG1 antibody with a single
glycosylation site, and CH2 as the least stable domain, as a model
system to investigate CH-pi sugar-protein interactions with respect
to glycoprotein stability. There are different structural features of
MAbs that contribute to aggregation, for example exposed
hydrophobic regions [30,31]. The antibody that we investigated
as a model molecule has little exposed hydrophobicity within the
CDRs and is fairly stable. Heat stress was used as the approach to
protein destabilization in our accelerated aggregation experiments,
with the assumption that our results would be applicable at lower,
more physiological temperatures, albeit after a longer time.
Successful connection between accelerated and long-term results
for monoclonal antibodies is described in another manuscript from
Figure 1. Computer simulations indicate dynamic fluctuations and increasing surface exposure of a hydrophobic carbohydrate-
interacting residue. (A) a schematic of an IgG antibody. (B) N-linked carbohydrates at Asn297 that constitute the G0 glycosylation pattern are in
black. The other heterogeneously included hexoses are in grey. (C) a view of all hydrophobic amino acids in the Fc region of IgG1 (polar and charged
amino acids are excluded from this representation), and a close-up view of the most hydrophobic motif on the inner side of CH2 that interacts with
carbohydrates. (D) SAA values calculated for Phe241 on chain A (left) and chain B (right) in the antibody Fc fragment assuming presence and absence
of glycosylation.
doi:10.1371/journal.pone.0008425.g001
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fluorescence and molecular biology approaches indicate a
reorganization of protein-carbohydrate interactions when the
glycoprotein is stressed.
Results
Peptide-Carbohydrate Fluctuations Increase Surface
Exposure of Phe241
Using the SAA (solvent accessible area) values from simulation,
we tested whether a highly hydrophobic region within the Fc
fragment that interacts with the carbohydrate moiety is dynam-
ically exposed. A G0 glycosylation pattern (Figure 1B) for both
chains A and B was used in the computer simulations. Two
different SAA values were calculated: first, SAA with glycosylation;
second, SAA without glycosylation (here the simulation was
performed with glycosylation, but the sugar groups were removed
only while calculating SAA). The SAA value with glycosylation
indicates if the hydrophobic group is exposed to the solvent.
Comparing this value with the SAA without glycosylation tells us
whether this hydrophobic group is masked from the solvent
through proximity to the Fc glycan. Figure 1 and Figure S1 show
the SAA values for Phe241, Leu242 and Phe243 of the Fc
fragment, each with two panels, one for heavy chain A, and one
for heavy chain B. The side chains of Phe241 and Phe243 face the
carbohydrates, while the side chain of Leu242 is buried in the
protein domain fold. We observe that the SAA with glycosylation
stays low without reaching the value of non-glycosylated case for
Phe241 in chain A, and for Phe243 in chain A and chain B.
Therefore, these residues are not significantly exposed to the
solvent. The SAA values for Leu242 also remain low and do not
depend on glycosylation. However, we notice that for Phe241 in
chain B the SAA value for the glycosylated case increases and
reaches the value of that of the non-glycosylated case. This shows
that Phe241 gets exposed due to dynamic fluctuations of the
carbohydrates, thereby leading to an exposed hydrophobic region
that could cause aggregation.
Protein-Carbohydrate Interactions Are Disrupted upon
Heat Stress
We monitored the dynamics of protein-carbohydrate interac-
tions by fluorescence of labeled IgG1 antibody at specific sites. We
generated 4 variants with a single surface-exposed amino acid
substituted with cysteine (Figure 2A). Variant 1, K248C, carries a
substitution at the CH2-CH3 junction, Variant 2, K326C, in CH2
at the lower hinge region, Variant 3, T22C, in VL, and Variant 4,
T197C, in CL. Because of the presence of two chains in an
antibody molecule, each variant has two surface cysteines,
however in the figures presented here, the mutated sites on only
one of the chains are shown. The cysteine variants, with
glycosylation profile similar to wild type, were used for site-
specific conjugation of maleimide-attached fluorophores (Figure 2
and Figure S2). On each variant, we also used hydrazide chemistry
for attaching fluorophores at oxidized carbohydrates.
Variants 1–4 were expressed at comparable levels of 10–30 mg/
L. The structures of all fluorophores used in this study are
presented in Figure S2. The specificity of cysteine labeling was
confirmed by proteolytic treatment and protein gel electrophore-
sis. Denaturing gel electrophoresis under reducing conditions
permits distinction of labeling at the light or heavy chain for the
four cysteine variants (Figure S2) and [33]. Peptide separation of
endoprotease Glu-C and pronase-treated samples further points to
the site-specific labeling of the variants (Figure S2). Each of the
four variants, labeled at the engineered surface cysteines, remain
more than 95% monomeric as determined by size-exclusion high
performance liquid chromatography (SEC-HPLC) (Figure S2),
and retain 80%–130% biological activity compared to wild type
[33]. Specificity of labeling at the carbohydrates was confirmed by
loss of fluorescence in the heavy chain upon PNGase F treatment;
loss of monomer upon carbohydrate labeling up to 20% was
observed by SEC-HPLC (Figure S2).
Each dual-labeled antibody variant was subjected to heat stress,
and fluorescence emission spectra of stressed and unstressed
samples were analyzed. The results indicate reduction of
fluorescence resonance energy transfer (FRET) between donor
and acceptor upon heat stress (Figure 2). For example, in the
native state of Variant 2, there is a prominent peak for the
acceptor fluorophore and a much smaller peak for the donor
fluorophore, indicating high FRET and short distance between the
fluorophores. When Variant 2 is stressed, the acceptor peak
decreases and the donor peak increases, indicating less FRET and
longer distance between the fluorophores in this condition. The
distance between the donor and acceptor fluorophores at the final
state increases the most for Variant 2 (10.0 A ˚), and to a smaller
extent for Variant 1 (7.2 A ˚), Variant 4 (5.0 A ˚) and Variant 3 (3.5
A ˚). The average of donor to acceptor intensity ratios and the
calculated distances in the native (time 0 hrs) and stressed (time
2 hrs) states are shown in Figure S2.
Protein-Protein and Carbohydrate-Carbohydrate
Interactions in the CH2 Domain Increase upon Stress
We used the same set of cysteine variants to monitor protein-
protein interactions. This time, pyrene maleimide was used for
conjugation to the engineered surface cysteines in Variants 1–4.
Pyrene is a fluorescent molecule with a characteristic increase in
emission at 465 nm, referred to as excimer, when two pyrene
molecules are in immediate (,10A ˚) proximity. Variants 1 and 2
show an increase by 140% and 160% in excimer fluorescence
upon stress at 60uC for 2 hrs; Variants 3 and 4 show a very slight
decrease or increase of excimer fluorescence (Figure 3A–3C).
Thus, protein-protein interactions increase specifically in the CH2
domain upon heat stress.
In addition, we probed for carbohydrate-carbohydrate inter-
molecular interactions by FRET. One population of antibody wild
type was labeled at the carbohydrates with donor (Alexa350
hydrazide), and another with acceptor (Alexa488 hydrazide).
Donor, acceptor and donor-and-acceptor samples were analyzed
before and after stress (Figure 3D–3F). After heating at 60uC for
2 hours, the mixture of donor and acceptor produces more FRET
(higher IA/ID ratio) than the non-stressed sample, indicative of
increased intermolecular interactions of the carbohydrate moieties.
The calculated distances from the FRET results correspond to
carbohydrates of neighboring antibody molecules being closer by
3.6 A ˚ on average after stress.
Carbohydrate Interactions with Aromatic Amino Acids
Are Important for CH2 Stability
To further explore the role of protein-carbohydrate interactions
experimentally, we generated two antibody mutants, F241S F243S
(Variant FS), and F241Y F243Y (Variant FY) (Figure 4A). Variant
FS has Phe residues, known to interact with the carbohydrate
moiety [25,26], replaced with polar serine residues that have
smaller and non-aromatic side chains. In Variant FY the same Phe
residues are replaced by Tyr residues, suggested to have higher
sugar interface propensity [23]. At the same time, other
hydrophobic residues, for example Val264, remain unmodified
in this region. Both wild type and Variant FY have very little if any
Protein-Carbohydrate Dynamics
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molecules of Variant FS bear at least one sialic acid residue
(Figure 4B).
The stability of wild type and Variants FS and FY was
compared in accelerated aggregation experiments and by
differential scanning micro-calorimetry (DSC). Samples at
150 mg/ml were induced to aggregate at 58uC for up to 36 hrs,
and monomer levels were resolved and quantified by SEC-HPLC
(Figure 4C). Wild-type monomer levels gradually decrease from
100 to 96, 91, and 87% for 0, 12, 24, and 36 hrs time points.
Variant FY trails by 1–2% in the earlier time points but is at 88%
at 36 hrs, within statistical error of wild type. Variant FS is
significantly less stable at this temperature showing a monomer
decrease from 99% to 39% at 12 hrs, and to 20% at 24 hrs. The
36-hrs samples were not run on SEC-HPLC because of the
presence of abundant visible aggregates.
DSC results also differentiate between the variants and wild type
(Figure 4D). The melting temperature (Tm) of the CH2 domain
decreases from 73uC for wild type to 59uC for Variant FS. Minor
differences in Variant FS,not greater than 1uC, are observed for the
melting transitions of Fab and CH3 as well. Although the CH2
melting transition shoulder of Variant FY overlaps that of wild type,
the software fitting indicates lowering of the CH2T mt o7 1 uC, while
the other two Tm’s remain unchanged.
Figure 2. Peptide-carbohydrate interactions are disrupted upon heat stress. (A) a full-antibody cartoon illustrates the positions of the
variants with engineered surface cysteines, and labeling approach in this set of experiments. Carbohydrates were labeled with Alexa350 hydrazide
dye. Surface cysteines for each variant were labeled with Alexa488 maleimide dye. Variants 2 and 1 have surface cysteines engineered in the CH2
domain, and Variants 4 and 3 in the Fab region. (B) Ratiometric analysis of fluorescence data for double-labeled samples after heat stress at 60uC for
2 hours. Acceptor/donor ratios of stressed (2 hrs) and unstressed (0 hrs) samples are shown. The number above each pair of columns indicates the
change in distance between the donor and acceptor fluorophores in the initial and final state. (C) Steady-state fluorescence data for individual
double-labeled variants.
doi:10.1371/journal.pone.0008425.g002
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intermolecular interactions via pyrene-labeled cysteine variants. (B) Excimer ratio of non-stressed (0 hrs) and stressed (2 hrs at 60uC) samples. The
numbers above the pair of columns for each variant indicate the ratio of stressed (value of column in black) to unstressed (value of column in grey)
sample ratios. (C) Emission spectra of pyrene-labeled variants. (D) Experimental set-up for analyzing carbohydrate intermolecular interactions.
Antibody samples with carbohydrates labeled with donor, A350, or acceptor, A480, were analyzed separately and as a mixture. (E) Ratios of acceptor
and donor intensity in the mixed samples before and after stress at 60uC for 2 hours. The change in intermolecular average distance between the
fluorophores after stress is shown above the columns. (F) Fluorescence spectra of Donor only, Acceptor only, and Donor and Acceptor mixture for
each condition.
doi:10.1371/journal.pone.0008425.g003
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Variant FS to wild type, and to better understand the observed
decrease in stability. Variant FS retains the b-sheet-rich structure
as wild type (Figure S3A). The variant has different mobility
patterns compared to wild type on reducing as well as native gel
electrophoresis (Figure S3B and S3C). We also carried out
protease treatment experiments to compare protein surface
exposure in Variant FS and wild type. Digestion of the antibodies
with Glu-C is more efficient (more small fragments) for Variant FS
than wild type; that efficiency is largely equalized in the variant
and wild type deglycosylated counterparts, although some
differences persist (Figure S3D). Furthermore, Variant FS retains
full FcRn and partial FccRIa binding function but loses binding to
FccRII and FccRIII receptors (Table 1 and Table 2).
Discussion
Protein-carbohydrate interactions present a high level of
diversity and complexity in Biology and Pharmacology. We used
an antibody with a single glycosylation site to monitor the
dynamics of protein-carbohydrate interactions. Our results point
to intramolecular dissociation of carbohydrates from the adjacent
protein surface, and to increased intermolecular protein-protein
and carbohydrate-carbohydrate interactions upon stress. These
dynamic fluctuations promote antibody aggregation.
Our interest in protein-carbohydrate interactions with respect to
antibody stability originated from the observation that the most
hydrophobic motif in Fc is on the inner surface of CH2 that
interacts with carbohydrates. Moreover, computer simulations on
Fc of human IgG1 antibody provided initial evidence of the
transient exposure of hydrophobic amino acids in the CH2
domain. Even for as short of a time as 5 ns, one of the hydrophobic
carbohydrate-interacting residues, Phe241 on chain B, gets nearly
as exposed as the that residue would be in a non-glycosylated Fc
(Figure 1D). The results for Leu242 represent a useful negative
control since this amino acid is oriented inward towards the
immunoglobulin fold, and low surface exposure is not affected by
Figure 4. The IgG1 variants F241S F243S (FS) and F241Y F243Y (FY) illustrate the importance of CH-pi interactions for stability of
the CH2 antibody domain. (A) Close-up on the CH2 domain showing the location of the mutated residues on the inner side of CH2, and the
alignment of Phe241 and Phe243 aromatic rings with sugar rings. (B) Glycosylation profile of wild type and the two F241 F243 variants. The
percentage of the predominant glycoforms is listed. (C) Accelerated aggregation of wild type and variants at 58uC for the indicated time. Percent
monomer at each time point was calculated from SEC-HPLC analysis. (D) DSC thermograms of wild type and Variants FY and FS.
doi:10.1371/journal.pone.0008425.g004
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observe change in SAA values for Phe243 in Fc simulations (Figure
S1), and for Phe241 and Phe243 in full antibody simulations (not
shown). It is possible that the full antibody provides an additional
rigidity to the Fc domain, and thus only simulations on the more
flexible Fc domain pick up differences from thermodynamic
fluctuations. Still, the presented data provides valuable and
unprecedented information for a very computationally demanding
system. The positive result for Phe241 encouraged us to explore
the protein-carbohydrate interactions with respect to protein
stability in further detail.
Combinations of fluorophores attached at specific sites on
proteins permit intermolecular and intra-molecular FRET exper-
iments that reveal increase or decrease of interactions at different
conditions. We utilized a pair of fluorophores, Alexa350 and
Alexa488 that can undergo energy transfer when the fluorophores
are close together, with R0 of about 50 A ˚, the Fo ¨rster distance at
which energy transfer is 50% efficient (Invitrogen). For comparison,
the length of the Fab and Fc IgG domains is about 50 A ˚ each, with
thefullantibodylengthvaryingbetween50A ˚ and100A ˚,depending
on the extension of the Fab domains from Fc in the hinge region.
We also utilized another fluorophore, pyrene, with a characteristic
excimer peak when two pyrene molecules are less then 10 A ˚ apart.
Our intramolecular FRET experiments with Alexa350 and
Alexa488 indicate less FRET between the donor-labeled carbohy-
drates and acceptor-labeled adjacent protein residues when the
samples are stressed than in the original samples. This result is most
pronounced for variant 2 that has a labeled surface cysteine in the
lower hinge region of CH2. Consistent with the further location of
the labeled cysteines in Variants 1, 4, and 3 from the carbohydrate
moiety, a smaller difference in FRET is observed for these variants
upon stress than for Variant 2.
Although we used accelerated stress conditions of high protein
concentration and high temperature for this set of FRET
experiments, we expect that our results will be representative for
lower temperature conditions after a longer stress time. We
established a mathematical model that successfully predicts long-
term aggregation data based on accelerated aggregation experiments
[32]. The fluorophores we used in our experiments as site-specific
reporters of structural dynamics are extrinsically attached probes with
properties on their own. However, the fact that labeled antibodies
retain most of their activity indicates that the fluorophores do not
perturb the structure of the antibodies. With the consistent
comparison of fluorescence across all four variants, we believe our
results represent the variants’ site dynamics and not the probes’
intrinsic properties. Moreover, when we label K326C (Variant 2) in
t h ea n t i b o d yw il dt yp ea n di nt h eV a r i a n tF Sb a c k g r o u n d ,w eo b s e r ve
two times more aggregates in Variant K326C FS than in Variant
K326C WT(not shown), consistent with the lower stability of Variant
FS compared to WT. This result suggests that the aggregation
patterns we observe of our labeled samples are a function of the
unlabeled protein stability, and not of the attached fluorophore.
Many mutations have been generated in the Fc region mostly for
the purpose of modulating Fc Receptor binding [34]. Thus, there is
abundant literature on amino acid mutations known to affect
receptor binding or glycosylation pattern [34,35]. However, few
CH2 mutations have been used in stability analysis. Variant FS
(F241SF243S) and FY (F241Y F243Y) permitelucidation of the role
of protein-carbohydrate interactions in CH2 domainstability. Unlike
other destabilized CH2 antibody variants such as deglycosylated
variants [12], Variant FS is more fully glycosylated (Figure 4B).
Similarly to the finding that deglycosylated human IgG showshigher
protein hydrophobicity exposure [27], Variant FS is more
susceptible to proteolytic digest (Figure S3D), indicative of higher
exposure of protein surface than wild type. The different Glu-C
digestive pattern of deglycosylated wild type and Variant FS suggests
the presence of structural differences apart from carbohydrate-
protein binding. Structural differences between Variant FS and wild
type are also reflected in the loss of binding of the variant to FccRII
and FccRIII receptors. Altogether, the results indicate that in
Variant FS the carbohydrates and protein form fewer contacts, and
that disruption of carbohydrate-pi interactions leads to structural
changes and to a significant reduction in antibody stability.
In contrast to Variant FS, Variant FY (F241Y F243Y) carries a
conservative mutation with respect to CH-pi interactions, and
remains fairly stable. Variant FY trails wild type by only 1–2% in
accelerated aggregation experiments at 12 and 24 hrs, and
narrowly surpasses wild type at 36 hrs. We do not believe that
the observed differences in aggregation kinetics are a result of the
higher G2 glycosylation levels of Variant FY because another wild
type sample (Figure S2) has similar G2 glycosylation levels. The
change of aggregation kinetics in Variant FY in comparison to
wild type may occur if the introduced mutation stabilizes a
subpopulation of the original sample or an intermediate.
Antibody molecules can assume a number of orientations
during aggregation. Our results point to interactions in the CH2
domain as a mechanism of antibody aggregation. Such interac-
tions may occur by parallel, angled or anti-parallel stacking of
molecules (Figure 5). We suggest the angled orientation as an
alternative to the parallel stacking for improved 3-dimensional
distribution of the Fab domains. A salient feature in all three
examples is the presence of intermolecular interactions between
protein patches that become exposed due to protein-carbohydrate
fluctuations. For simplicity, here we discuss models of interactions
between the dynamically exposed patches, although in reality such
patches may interact also with existing surface-exposed patches.
In the parallel and angled orientations, the molecules are only
partially overlapping, so that the front patch of one molecule can
Table 1. Equilibrium dissociation constants KD of antibody wild type and Variant FS to Fc receptors.
Mab FccRIIa FccRIIb FccRIIIa F158 FccRIIIa V158 FccRIIIb FcRn pH 6.0
WT 5.4 mM2 4 mM1 2 mM5 . 0 mM3 0 mM2 . 6 mM
FS No binding No binding No binding No binding No binding 2.7 mM
doi:10.1371/journal.pone.0008425.t001
Table 2. Kinetic rate constants kon and koff of antibody wild
type and Variant FS binding to FccRIa.
MAb kon (M
21s
21)k off (s
21)K D (M) Rmax (RU)
WT 4.5610
4 8.2610
24 1.8610
28 479
FS 2.9610
4 2.1610
23 7.4610
28 126
doi:10.1371/journal.pone.0008425.t002
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anti-parallel orientation has both Chain A and Chain B of the
molecules overlap to facilitate proximity of the patches from one of
the chains. The fluorescence results presented in this report suggest
increased protein interactions in the CH2 domain but no change in
the light chain in Fab, and at the same time increased proximity of
carbohydrates from adjacent molecules. The Fab domains are the
furthest apart in the anti-parallel orientation, but at the same time
the carbohydrates, the lower hinge region of CH2, and the CH2-
CH3 junction, are the closest in the parallel or angled orientation.
Although all three orientations are possible, as well as others,
additional fluorescence experiments can delineate the predomi-
nant aggregating orientation.
Collectively, our results point to a mechanism of antibody
aggregation where native protein-carbohydrate interactions are
disrupted, and newly exposed sites interact and contribute to
aggregation. This model is consistent with previously reported
results. It has been shown that partially or fully deglycosylated CH2
domains have lower melting transitions than wild type (a mixture of
G0, G1, G2, and sialylated antibody) [12]. In addition, removal of
carbohydrates leads to a closed conformation of CH2 [26],
suggestive of the capacity of the usually protected protein surfaces
to interact. Furthermore, dynamic motion of G0-glycosylated
antibodies has been observed by NMR, and increased carbohydrate
exposure has been implicated in activating the complement system
via interactions with the mannose-binding lectin (MBL) [28,29].
The molecular level insights from our work extend to at least
two areas. First, the correlation of our results and the literature on
MBL binding suggests that antibody aggregation may be
immunogenic not only because antibody multimers are perceived
as foreign, but also because stress- and time-induced exposure of
antibody carbohydrates leads to activation of the complement
system via MBL. Second, our results suggest an aggregation
mechanism for antibodies generated against carbohydrate-based
targets. Considering the prevalence of aromatic, hydrophobic
residues in carbohydrate binding sites, most antibodies that come
out of the Discovery phase in pharmaceutical research to target
carbohydrates are likely to have Phe, Tyr or Trp in their CDR
regions. The high surface exposure of such amino acids is likely to
be a driving force of intermolecular interactions that lead to high
aggregation propensity in vitro. Thus, the results presented here
indicate the importance of antibody protein-carbohydrate dynam-
ic interactions in stability and function.
Materials and Methods
Computer Simulation
Molecular dynamics simulations were performed for the Fc
fragment of a human IgG1 antibody using the CHARMM
simulation package [36]. Here we used an explicit solvent model.
The CHARMM fully atomistic force field [37] was used for the
protein, and TIP3P [38] model for water. The simulations were
performed at 300K and 1atm in the NPT ensemble. The Fc
fragmentwassimulated with the inclusion ofdisulphidebondsinthe
hinge region. A G0 glycosylation pattern was used where the
parametersforthe sugargroupswerederivedinconsistence withthe
CHARMM force field, following from the CSFF force field [39].
DNA Vectors and Mutagenesis
Vectors encoding the light and heavy chains of a proprietary
human IgG1 antibody were kindly provided by Dr. Burkhard
Wilms at Novartis. The light and heavy chain genes were subcloned
in vector gWIZ (Genlantis), engineered for protein expression by
transient transfection of mammalian cells. Antibody variants were
either de novo synthesized (GeneArt) or generated by in-house site-
directed mutagenic PCR and confirmed by sequencing.
Protein Expression and Purification
Antibody wild type and variants were expressed at 10–100 mg
levels by transient transfection of Freestyle HEK 293 cells
(Invitrogen) with polyethyleneimine (Polysciences) as the transfec-
tion reagent. Cell culture supernatant was collected 7–10 days
post-transfection. Antibodies were purified on a protein A column
(GE Healthcare), eluted with 50 mM citrate buffer, pH 3.5, and
buffer exchange in 20 mM His, pH 6.5 buffer for stability analysis
or 50 mM Tris buffer for fluorescence labeling.
Protein Labeling
Labeling of cysteine variants was carried out first by treatment
with L-cysteine to decap the engineered surface cysteine, followed
Figure 5. Model of an aggregation mechanism of IgG antibodies. (A) Native antibodies have carbohydrates that interact with neighboring
amino acids on the inner side of CH2. The light and heavy chains are presented in grey. The sugars are shown as a black bar, attached to Asn297, a
black dot. White ovals represent a patch in CH2 that is usually masked by the carbohydrates. (B–D) Dynamic motion of carbohydrates transiently
exposes underlying protein hydrophobic residues. Stress, such as heat, exacerbates that motion, exposing aggregation-prone region, and resultingi n
protein aggregation where new glycoprotein interactions are formed. One antibody molecule is in light grey, and the other in dark grey. (B) Parallel
stacking of full antibodies resulting from interactions between newly exposed protein patches. (C) Angled stacking for improved interaction between
exposed protein patches. (D) anti-parallel stacking of full antibodies with interactions between newly exposed protein patches.
doi:10.1371/journal.pone.0008425.g005
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5–10-fold excess of Alexa488 maleimide dye (Invitrogen) for 1 hr
at room temperature or with 10-fold excess of Pyrene maleimide
dye (Invitrogen) for 12 hrs at room temperature. After removal of
free dye, and buffer exchange to 50 mM phosphate buffer pH 7.0,
the efficiency of protein labeling was calculated as mole of dye per
mole of protein according to manufacturer’s protocols (Invitro-
gen). Labeling with Alexa488 yielded efficiency of 1.5–2.0, and
with Pyrene of 0.8–1.0.
Antibody carbohydrates were labeled with Alexa350 hydrazide
and Alexa488 hydrazide (Invitrogen) following a carbohydrate
labeling protocol (Pierce), using sodium meta-periodate for
oxidation of carbohydrate hydroxyl groups to aldehydes, and
protein incubation with 10-fold dye excess at room temperature
for 12 hrs. Labeling efficiencies were in the 1.0–1.5 range of mole
dye per mole protein.
Fluorescence Analysis
Steady-state fluorescence experiments were carried out on
Fluorolog (Horiba Jobin Yvon). Samples at 50 mg/ml were
stressed at 60uC for 2 hours, diluted 30-fold and placed on ice
until analysis. For pyrene analysis, excitation was at 342 nm, and
emission was recorded from 347 to 600 nm. The ratio of excimer
signal intensity at 465 nm to a basal signal intensity at 375 nm was
calculated for each samples. Samples labeled with Alexa350 and
Alexa488 were excited at 347 nm, and emission was recorded
from 350 to 650 nm. Distances between Alexa fluorophores were
calculated assuming Fo ¨rster’s distance R0 for Alexa350 and
Alexa488 of 50A ˚ and k
2 of 2/3. Then, change in distance upon
stress from time t=0 hrs (r0), to time t=2 hrs (r2) was calculated
based on the measured emission intensity of donor and acceptor
(ID and IA) at the corresponding time points with the equation:
D distance ~ r2{ r0~ R0 ID2=IA2 ðÞ
1=6{ ID0=IA0 ðÞ
1=6

Stability Analysis
Size-exclusion High Performance Liquid Chromatography
(SEC-HPLC) was used to determine monomer loss over time in
accelerated aggregation experiments. Antibody wild type and
variants FS and FY were incubated at 150 mg/ml at 58uC for up
to 36 hours. For each time point, sample aliquots of 2 ml were
diluted 15-fold in 15 mM potassium phosphate buffer, pH 6.5 to
10 mg/ml. Monomers were resolved from non-monomeric species
by SEC-HPLC on a TSKgel Super SW3000 column (TOSOH
Bioscience), kept at 22uC, with mobile phase 150 mM potassium
phosphate, pH 6.5, and flow rate of 0.2 ml/min. Percent
monomer was calculated as the area of the monomeric peak
divided by the total area of all peaks detected at 280 nm.
The thermodynamic stability of antibody wild type and variants
FS and FY was compared by Differential Scanning Micro-
calorimetry (DSC, Microcal). Samples were analyzed at a
concentration of 2 mg/ml in 20 mM His pH 6.5 buffer and at
1.0uC/min scan rate. The sample data was analyzed by
subtraction of the reference data, normalization to the protein
concentration and DSC cell volume, and interpolation of a cubic
baseline. The peaks were deconvoluted by non-2-state fit using
Microcal Origin 5.0 software.
PNGase F (New England Biolabs) and Glu C (Sigma) were used
for protein digests according to manufacturers’ protocols. Reduced
and non-reduced antibody samples were resolved on SDS-PAGE
(BioRad). Native gel electrophoresis was carried out in 1% agarose
gels in 30 mM His, pH 6.0 buffer system.
Glycosylation Pattern Analysis
Glycans of the MAb wild type and variants were released with
PNGase F. After separation of the oligosaccharides from the
protein, the glycans were labeled with 2-Amino-benzamide. The
excess dye was removed prior to normal phase liquid chromatog-
raphy (NP-LC) measurements, performed with an Agilent 1100
HPLC coupled to Bruker Esquire 3000 ion trap mass spectrom-
eter. Glycan identification was performed by referencing NP-LC
retention times and comparing measured with theoretical
molecular weight. Percent peak area was obtained by integrating
the fluorescence-label signals and comparing with the total peak
area.
FcR Binding
Recombinant extracellular domains of Fc receptors were
immobilized covalently or through enzymatic, site-directed
biotinylation on suitable sensorchips, and affinity of antibodies to
Fc receptors was determined through steady-state analysis at
pH 7.4 (FccRII, FccRIII) or pH 6.0 (FcRn) or kinetic analysis at
pH 7.4 (FccRIa) on a Biacore 3000 instrument.
Supporting Information
Figure S1 Computer simulations
Found at: doi:10.1371/journal.pone.0008425.s001 (0.11 MB
DOC)
Figure S2 Results from FRET experiments
Found at: doi:10.1371/journal.pone.0008425.s002 (0.23 MB
DOC)
Figure S3 Structural comparison of wild type and Variant FS
Found at: doi:10.1371/journal.pone.0008425.s003 (0.77 MB
DOC)
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